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INTRODUCTION 
 The development of inhibitors to factor VIII (FVIII) has become 
one of the most serious complications in the treatment of 
haemophilia patients, occurring in 15-30% of haemophilia A (HA) 
patients and 1-3% of haemophilia B (HB) patients. (1) 
The management of acute bleeding episodes may use different 
approaches: human factor VIII or factor IX (2), porcine factor VIII 
(3), prothrombin complex concentrates (PCC), activated 
prothrombin complex concentrates (aPCC) (4-6) and more recently 
recombinant activated factor VII (rFVIIa, Novoseven) (7). 
rVIIa is a potent by-passing agent which mechanism of action is 
most probably to provide a full thrombin burst, in the absence of 
FVIII/FIX, on the activated platelets and represents a major 
therapeutic advance in the treatment of haemophilia patients with 
high-titter inhibitor (8). Its safety and efficacy in the treatment of 
haemophiliacs with inhibitors to FVIII or IX has been investigated in 
clinical studies since 1989 (9).  
RFVIIa has been used in our country for the first time, in 
Compassionate Use Program, in November 1994. Since 1996 foi 
comercializado em Portugal e utilizado no tratamento dos doentes 
com hemofilia e inibidores. 
The aim of this study is to evaluate, retrospectively, the efficacy and 
safety of rFVIIa in the treatment of acute bleeding episodes and 
prophylactic, in surgical procedures, in the period between 
Nov.1994-Dec1999, in the patients followed in Hospital S. José and 
Hospital de Santa Maria in Lisbon.   
PATIENTS AND METHODS 
The patient population consisted of 15 patients, 14 had hemophilia 
A (13 severe, 1 mild) and 1 had severe hemophilia B; mean age 
25,7 years (range: 4-50), mean weight 56.4 Kg (range :22-100). 
RFVIIa was used in the treatment of 90 acute bleeding episodes. 
(Table 1) 
2 patients have been treated on a compassionate use basis, in two 
lifethreatening bleeding episodes. 
In the treatment of acute hemarthroses rFVIIa was administered by 
intravenous bolus injection in the dose range 80-90mcg/Kg. The 
initial dose was given every 2 h, in a total of 3 injections or until 
clinical improvement was observed.  
O tratamento dos hematomas intramusculares, (including psoas-
iliac hematomas), dos hematomas retroperitoneais e do subdural 
hematoma foi efectuado com rFIIa em Bolus Intermitent Injections 
(BII), na dosagem de 80-100mcg/Kg, de 2/2 h nas primeira 24 
horas, com alargamento dos intervalos para 3/3, 4/4 e 6/6 horas, de 
acordo com a sintomatologia clínica e  os exames de controlo. 
Quando usado em profilaxia em casos de cirurgia urgente o 
procedimento foi idêntico, variando o nº de dias de tratamento.   
The efficacy was assessed as: an excellent/effective (E) response 
was defined when the bleeding ceased or decreased substantially, or 
when there was a significant relief of pain and swelling within 8-12 
hours; a partially effective (PE) response was defined as some relief 
of symptoms, or an improvement of mobility but the bleeding 
continued; no clinical improvement or if bleeding remained or 
worsened, there was an ineffective response (IR). 
Epsilon aminocaproic acid, 100 mg/Kg, every 6 h, foi utilizado 
como terapêutica adjuvante, nos casos de cirurgia, hemorragias das 
mucosas e na extracção dentária. 
Laboratory monitoring included platelet count, estimations of  
prothrombin time (PT/INR) and levels of factor VII:C. Both FVII:C 
and PT/INR were performed by a one-stage assay, using a rabbit 
brain thromboplastin. 
Case nº Hem. type Age Type of bleed 
1 A 23 Subdural haematoma* (1) 
2 A 40 Post-nefrectomy abdom.haematoma(1) 
3 A 15 
Joint bleed (3) Muscle bleed(2) 
Respiratory tract bleed (1) 
Prophylatic of lumbar puncture (1) 
4 A 23 Oral cavity bleed (1) Nose bleed (1) 
5 A 18 
Joint bleed (3) Muscle bleed (4) 
Retroperitoneal hemorrhage (2) 
Dental bleed (2) Tongue bleed (1) 
6 A 14 Joint bleed (5) Gastrointestinal bleed (1) 
7 A 29 Joint bleed (17) Gastrointestinal bleed (1) 
8 A 41 Circumcision (1) Joint bleed (2) 
9 A 35 Neck Muscle bleed (1) 
10 A 50 Muscle bleed (3) 
11 A 31 Retroperitoneal hemorrhage (1) 
12 A 29 Joint bleed (3) Muscle bleed (1) 
13 A 6 
Radioactive synoviorthesis (2) 
Central catheter removal (1) 
Joint bleed (9) 
14 B 4 Subdural haematoma/craniotomy* (1) 
15 A 27 Joint bleed (19) 
RESULTS 
EFFICACY 
Joint bleeds (Fig.1): an excellent/effective response to treatment 
was observed in 48 (79%) episodes. In 8 (13%) episodes the 
response was evaluated as partially effective and in 5 (8%) 
ineffective. 
Mean treatment/episode: 3,2 (range:1-9). 
Partially effective and ineffective responses are related to target 
joints (knee, elbow) assim como o maior nº de tratamentos por 
episódio. In one patient (pte. 15) in home treatment, all the joint 
bleeds were evaluated as effective, and  the mean treatment per 
episode was 2,6 (range: 1-6). 
Muscle bleeds (Fig 1): In this group of 11 episodes we included one 
ilio-psoas haematoma and 10 other intramuscular haematomas 
(thigh, calf, lombar, neck). 
The response to treatment was evaluated as excellent/effective in 9 
(82%) episodes, partially effective in one case (4%) and ineffective 
in one case (4%). Mean treatment/episode -  15,5 (range:3-45). 
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Prophylactic (Table 2) - rFVIIa proved to be very effective in five 
(83%) episodes, with an excellent recovery of the child (pte. 14) 
with the subdural haematoma, with complete recovery of the 
neurological symptoms. In one case (pte.5) satisfactory haemostasis 
was not achieved, for dental extraction, with subsequent oozing, 
probabilly because of suboptimal rFVIIa and/or antifibrinolytic 




























































































Table 2 – Novoseven use in prophylaxis, number of doses per episode 
 and efficacy  
Table 1 – Characteristics of the patients given rFVIIa and bleeding episodes. 
Table 3- Novoseven use in other hemorrhages, number of  
treatments per episode and efficacy. 
Figure 1- Joint and muscle bleeds treatment efficacy. 
Partially effective (13.11%)Ineffective (8.20%)
Effective (78.69%)
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Retroperitoneal hematomas – an excellent response was observed 
in all cases, with evident relief of pain, less than 24 hours after the 
beginning of the treatment. 
Other haemorrhages (Table 3) - an excellent/effective response was 
observed in 7 episodes (87,5%) and a partially effective response in 
the case of the tongue haemorrhage. The patient had a dental 
spicule that caused trauma and after dental correction the 
haemorrhage stopped.  
Mean treatment/episode: 13,4 (range: 2-36). 
Partially effective (13.33%)Ineffective (6.67%)
Effective (80.00%)
Global Efficacy
LABORATORY MONITORING- Although the therapeutic level of 
rFVII:C is not yet well established, our target was to 
maintain plasma FVII:C level above 10U/mL. The levels of 
post-infusion FVII:C had been determined in 5 cases. The 
highest FVII:C level recorded in each individual range from 
8,7 to 23,4U/mL. These differences may be related to 
differences in individual recovery of rFVIIa.  
ADVERSE EVENTS- A total of 4 non-serious adverse events 
were recorded: local thrombophlebitis (3  cases) and fever 
and cutaneous erythema (1 case).  
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